Etiology and Pathogenesis > Hereditary Tumor Syndromes

Abstract

Moore SK, Zambrano N, Lynch HT, Lipkin M, Kopelovich L

Food and Drug Administration, Center for Drug Evaluation and Research, Rockville, Maryland, USA

Although acquired mutations in the human p53 gene occur in many tumor types, germline mutations are rare. 
An exception is the occurrence of germline p53 mutations in a fraction of families afflicted with the Li-Fraumeni syndrome (LFS). 
Previous studies from our laboratory demonstrated increased levels of wild type p53 protein in skin fibroblasts (SF) of patients from heritable cancer syndrome, including familial adenomatous polyposis (FAP), neurofibromatosis type 1 (NF1), and bilateral retinoblastoma (bRB) (Kopelovich and DeLeo, 1984,1986). 
Here, we further address the association between germline p53 alterations and genetic predisposition to cancer in the SBLA syndrome and in FAP. 
DNA sequencing and single-stranded conformational polymorphism analysis (SSCP) were utilized to screen for the presence of mutations within exons 5-9 of the p53 gene in SF and in benign tumors. 
Thus we observed no germline mutations in exons 5-9 of the p53 gene in SF from SBLA or FAP patients, including the Gardner variant. 
In addition, we observed no acquired mutations in exons 5-9 of the p53 gene in benign tumors from FAP patients. 
In conclusion, we found no association between germline p53 mutations and SBLA or FAP. 
How mechanisms that involve nonmutational activation of the p53 protein might affect genetic predisposition to cancer remains to be established.

PMID: 8830720 [PubMed - indexed for MEDLINE]